Di Bello Francesco, Rodriguez Peñaranda Natali, Siech Carolin, de Angelis Mario, Tian Zhe, Goyal Jordan A, Collà Ruvolo Claudia, Califano Gianluigi, Creta Massimiliano, Saad Fred, Shariat Shahrokh F, Briganti Alberto, Chun Felix K H, Puliatti Stefano, Longo Nicola, Karakiewicz Pierre I
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Ann Surg Oncol. 2025 Mar;32(3):2226-2232. doi: 10.1245/s10434-024-16639-1. Epub 2024 Dec 3.
Perioperative complication rates and in-hospital mortality after radical nephroureterectomy (RNU) in patients with a history of heart valve replacement are unknown.
Within the National Inpatient Sample (2000-2019), we identified non-metastatic upper urinary tract carcinoma patients treated with RNU according to the presence or absence of a history of heart valve replacement. Propensity score matching (1:10 ratio) and multivariable logistic regression as well as Poisson regression models were used.
Of 15,423 RNU patients, 151 (1.0%) harbored heart valve replacement. This proportion increased over the study span from 0.5% to 1.4% (p = 0.02). Heart valve replacement patients were older (median 78 vs. 72 years; p < 0.001), more frequently male (73 vs. 60%; p = 0.002), and more frequently harbored a Charlson Comorbidity Index (CCI) ≥3 (36 vs. 27%; p = 0.002). After 1:10 propensity score matching for age, sex, and CCI, the patients exhibited higher rates of perioperative bleeding (7.4 vs. 2.4%; odds ratio [OR] 3.2; p < 0.001), blood transfusions (24.0 vs. 17.0%; OR 1.6; p = 0.02), and cardiac complications (24.0 vs. 14.0%; OR 2.1; p < 0.001). Conversely, heart valve replacement patients did not exhibit higher rates of critical care therapy (OR 1.06; p = 0.8), higher rates of in-hospital mortality (OR 0.8; p = 0.8), and longer length of stay (OR 1.4; p = 0.052) than their RNU counterparts without a history of heart valve replacement.
RNU patients with a history of heart valve replacement are at significantly increased risk of perioperative bleeding, blood transfusions, and cardiac complications; however, despite these increased risks, they neither exhibited higher critical care therapy rates or higher in-hospital mortality rates, nor did they require significantly longer hospital stay.
有心脏瓣膜置换史的患者行根治性肾输尿管切除术(RNU)后的围手术期并发症发生率和院内死亡率尚不清楚。
在国家住院患者样本(2000 - 2019年)中,我们根据是否有心脏瓣膜置换史,确定接受RNU治疗的非转移性上尿路癌患者。使用倾向评分匹配(1:10比例)、多变量逻辑回归以及泊松回归模型。
在15423例RNU患者中,151例(1.0%)有心脏瓣膜置换史。这一比例在研究期间从0.5%增加到1.4%(p = 0.02)。有心脏瓣膜置换史的患者年龄更大(中位数78岁对72岁;p < 0.001),男性更常见(73%对60%;p = 0.002),且更频繁地患有Charlson合并症指数(CCI)≥3(36%对27%;p = 0.002)。在按年龄、性别和CCI进行1:10倾向评分匹配后,这些患者围手术期出血率更高(7.4%对2.4%;优势比[OR] 3.2;p < 0.001)、输血率更高(24.0%对17.0%;OR 1.6;p = 0.02)以及心脏并发症发生率更高(24.0%对14.0%;OR 2.1;p < 0.001)。相反,有心脏瓣膜置换史的患者与无心脏瓣膜置换史的RNU患者相比,重症监护治疗率没有更高(OR 1.06;p = 0.8),院内死亡率没有更高(OR 0.8;p = 0.8),住院时间也没有显著延长(OR 1.4;p = 0.052)。
有心脏瓣膜置换史的RNU患者围手术期出血、输血和心脏并发症的风险显著增加;然而,尽管有这些增加的风险,他们既没有更高的重症监护治疗率或更高的院内死亡率,也不需要显著更长的住院时间。